Burning Rock Biotech Limited (BNR) is a Guangzhou-based precision oncology company that develops next-generation sequencing (NGS) diagnostics for cancer therapy selection and early detection, operating through central laboratory, in-hospital, and pharma research services segments. Its American Depositary Shares traded at $13.61 late in Thursday's session, up $0.54, or 4.13%, from the prior close of $13.07. The direction is clearly higher, and the gain extends a 4.56% advance logged in the previous session. No verified news release, regulatory filing, analyst rating change, or major corporate development explains the move; the price action is best characterized as a continuation of a technical rebound in a thinly traded name ahead of an imminent quarterly update.
No verified news or fundamental catalyst found for Thursday's advance. No press release, Form 6-K, analyst note, or credible media report published before or during the session offers a company-specific explanation. The only recent disclosure was a routine notice of the company's 2026 annual general meeting, scheduled for December 22, which carries no operating implications and is too immaterial to justify a 4.13% move.
The most plausible assessment is that this is a mechanical rebound within an unusually wide trading channel. Shares peaked near $18.94 in late September, slid to $10.04 on November 2, then rallied back above $13.40 before slipping to $12.50 on November 17. The last two sessions have retraced that dip. With roughly 3.3 million ADS in the float and a market value near $144 million, modest buy orders can move the quote several percentage points, and the day's range of $12.39 to $13.88 shows exactly that kind of frictionless price discovery. Anticipation of the third-quarter report — due within days based on last year's November 20 release — may also be drawing speculative positioning.
Trading activity was not exceptional. Roughly 7,000 ADS changed hands in the first half of the session, a pace that points to full-day turnover at or below the average of about 35,000, well short of the more than 100,000 shares that traded during September's heaviest sessions. The price move was therefore achieved on light volume, which limits its informational value.
Technically, the stock pushed through its 50-day average near $13.84, touching an intraday high of $13.88 before easing. It remains far below the 52-week high of $41.72 and well above the 52-week low of $6.79, but up roughly 35% from the November 2 low. Small-cap oncology diagnostics has been volatile as a group, with double-digit swings common across liquid-biopsy and molecular-testing peers; the stock's implied volatility and volatility history remain elevated, so index-level moves are unlikely to be the driver here. Company-specific order flow, rather than broad market direction, dominates the tape in a name this small.
The score runs from 0, meaning no meaningful news and a move that is normal for the stock, to 100, meaning transformative verified news paired with an extreme, rare price move. This event scores 6 out of 100.
The news component is minimal: no verified catalyst was identified, and the company's size means even routine updates rarely justify outsized moves. The price component is equally subdued. At 4.13%, the gain was only about 0.7 times the stock's average absolute daily move of roughly 5.6% over the past 60 sessions, and equal or larger swings occurred in 35 of those 60 sessions. A routine move with no news combines into a very low score.
Attention turns to the third-quarter results, which are expected in the coming days and will be the first hard look at whether the company can stabilize revenue near the roughly $19 million quarterly run rate reported in the second quarter. The conference call will matter as much as the headline numbers, with investors focused on gross margin, operating cash burn, and the pace of in-hospital kit adoption in China. Analyst coverage is thin — a single rating with a target well below the current price — so the stock has little formal sell-side support to anchor expectations. Sector developments in China's NGS reimbursement landscape and any partner-driven companion diagnostic milestones are additional swing factors. Risks cut both ways: heavy losses and a sub-$150 million market value leave the shares exposed to sharp reversals, while the low float can amplify rallies just as easily.
Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are showcased in its curated Trending AI Robots section. Bots differ by strategy, timeframe, performance metrics, and the symbols they trade, so the featured list changes as market conditions shift. For traders who want to compare systematic approaches against their own research, reviewing the Trending AI Robots lineup is a practical next step.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where BNR advanced for three days, in 191 of 233 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
The Momentum Indicator moved above the 0 level on November 05, 2026. You may want to consider a long position or call options on BNR as a result. In 62 of 83 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 75%.
The Moving Average Convergence Divergence (MACD) for BNR just turned positive on November 06, 2026. Looking at past instances where BNR's MACD turned positive, the stock continued to rise in 36 of 46 cases over the following month. The odds of a continued upward trend are 78%.
BNR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 36 of 39 cases where BNR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
BNR moved below its 50-day moving average on October 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BNR crossed bearishly below the 50-day moving average on October 27, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BNR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for BNR entered a downward trend on November 11, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 42 (best 1 - 100 worst), indicating steady price growth. BNR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 47 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.258) is normal, around the industry mean (67.298). P/E Ratio (-1.157) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (1.741) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 82 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BNR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a company, which engages in the investment of medical fields and specializes in next-generation sequencing diagnostics solutions for precision medicine in oncology
Industry MedicalSpecialties